| PUBLICATIONS (Ranked by impact factor of the journal) | LABORATORY RESEARCH T cells Engineered with a T Cell Receptor against the Prostate Antigen TARP Specifically Kill HLA-A2+ Prostate and Breast Cancer Cells To produce genetically engineered T cells directed against prostate and breast cancer cells, scientists cloned the T-cell receptor recognizing the HLA-A2–restricted T-cell recptor γ- chain alternate reading-frame protein (TARP)4–13 epitope. TARP is a protein exclusively expressed in normal prostate epithelium and in adenocarcinomas of the prostate and breast. [Proc Natl Acad Sci USA ] Abstract | Press Release Activation of Nuclear Factor-Kappa B (NFκB) in Prostate Cancer Is Mediated by PKC Epsilon (PKCε) Investigators report that PKCε is an essential mediator of NF-κB activation in prostate cancer cells. A strong correlation exists between PKCε overexpression and NF-κB activation status in prostate cancer cells. [J Biol Chem] Full Article The Maternal Embryonic Leucine Zipper Kinase (MELK) Is Upregulated in High-Grade Prostate Cancer The concerted inhibition of MELK and other cell cycle targets by the antibiotic siomycin A strongly impaired cell viability of prostate cancer cells, and may point to a novel therapy approach for a subset of high-risk prostate cancer patients. [J Mol Med] Abstract Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment Polyethylene glycol (PEG) hydrogels, common cell-binding motifs in extracellular matrix proteins, and matrix metalloproteinase cleavage sites, were characterized regarding their stiffness, diffusive properties, and ability to support growth of androgen-dependent LNCaP prostate cancer cells. Researchers found that the mechanical properties modulated the growth kinetics of LNCaP cells in the PEG hydrogel. [PLoS One] Full Article Notch Activation Is Dispensable for D, L- Sulforaphane-Mediated Inhibition of Human Prostate Cancer Cell Migration Investigators determined the role of Notch signaling, which is constitutively active in many human cancers, in anticancer effects of D, L-sulforaphane using prostate cancer cells as a model. [PLoS One] Full Article Integrin Alphavbeta3 and CD44 Pathways in Metastatic Prostate Cancer Cells Support Osteoclastogenesis via a Runx2/Smad 5/Receptor Activator of NF-kappaB Ligand Signaling Axis Scientists previously demonstrated that prostate cancer cells secrete receptor activator of NF-kB ligand (RANKL), however, the mechanism(s) by which RANKL is produced remains to be determined. In the present study, they investigated the molecular mechanisms controlling RANKL expression in metastatic prostate cancer cells. [Mol Cancer] Abstract | Full Article Benzoxazinoids from Scoparia dulcis with Antiproliferative Activity against the DU-145 Human Prostate Cancer Cell Line Four compounds, along with eight known compounds were isolated from the aqueous extract of S. dulcis. The antiproliferative activities of the six benzoxazinoid compounds against the DU-145 human prostate cancer cell line were assayed. [Phytochemistry] Abstract Preclinical Evaluation of Sunitinib, a Multi- Tyrosine Kinase Inhibitor, as a Radiosensitizer for Human Prostate Cancer Researchers investigated the radiosensitizing effects of sunitinib, a potent, multi-tyrosine kinase inhibitor of the vascular endothelial growth factor receptor and platelet derived growth factor receptor, on human prostate cancer cells. [Radiat Oncol] Abstract | Full Article CLINICAL RESEARCH Efficacy of Cetuximab in Metastatic Castration- Resistant Prostate Cancer might Depend on EGFR and PTEN Expression: Results from a Phase II Trial Scientists investigated the combination of docetaxel and cetuximab, the monoclonal antibody against epidermal growth factor receptor (EGFR) in prostate cancer patients. [Clin Cancer Res] Abstract Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Ketoconazole: Association with Outcome and Predictive Nomogram Scientists assessed the association between the pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic castration-resistant prostate cancer treated with the CYP17 inhibitor ketoconazole. [Oncologist] Abstract
|
|
|
|